



**HAL**  
open science

## **Anxiety in Parkinson's disease is associated with changes in the brain fear circuit**

Guillaume Carey, Renaud Lopes, Romain Viard, Nacim Betrouni, Gregory Kuchcinski, Quentin Devignes, Luc Defebvre, Albert F.G. Leentjens, Kathy Dujardin

► **To cite this version:**

Guillaume Carey, Renaud Lopes, Romain Viard, Nacim Betrouni, Gregory Kuchcinski, et al.. Anxiety in Parkinson's disease is associated with changes in the brain fear circuit. *Parkinsonism & Related Disorders*, 2020, *Parkinsonism & Related Disorders*, pp.89-97. 10.1016/j.parkreldis.2020.09.020 . hal-03185859

**HAL Id: hal-03185859**

**<https://hal.univ-lille.fr/hal-03185859>**

Submitted on 30 Mar 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Anxiety in Parkinson's disease is associated with changes in the brain fear circuit

Guillaume Carey<sup>1</sup> MD, Renaud Lopes<sup>1,3</sup> PhD, Romain Viard<sup>1,3</sup> PhD, Nacim Betrouni<sup>1</sup> PhD, Gregory Kuchcinski<sup>1,3</sup> MD, Quentin Devignes<sup>1</sup> MSc, Luc Defebvre<sup>1,2</sup> MD PhD, Albert FG Leentjens<sup>4</sup> MD PhD, Kathy Dujardin<sup>1,2</sup> PhD.

1 Univ. Lille, Inserm, CHU Lille, Lille Neurosciences and Cognition, Lille, France

2 Neurology and movement disorders department, Lille University Medical Centre, Lille, France

3 Department of Neuroradiology, Lille University Medical Centre, Lille, France

4 Department of Psychiatry, Maastricht University Medical Centre, Maastricht, the Netherlands

## Correspondance to Guillaume Carey

CHU de Lille, Hôpital Roger Salengro, Service de Neurologie A,  
Avenue du Professeur Emile Laine,  
59037, Lille, France

e-mail: [guillaume.carey.etu@univ-lille.fr](mailto:guillaume.carey.etu@univ-lille.fr)

**Short title:** MRI markers of anxiety in Parkinson's disease

**Keywords:** Parkinson's disease; anxiety disorders; fear circuit; neuroimaging; amygdala

**Abbreviations:** 3D-T<sub>1</sub>w = 3 Dimension T<sub>1</sub>-weighted; A+ = patient group with anxiety; A- = patient group without anxiety; ACC = Anterior Cingulate Cortex; BJLO = Benton judgment of line orientation test; BNT = Boston naming test; dlPFC = dorsolateral prefrontal cortex; FDR = false discovery rate; GLCM = Grey-Level Co-occurrence Matrix; HAMD = Hamilton Depression Rating Scale; HVLT = Hopkins verbal learning test; IC = insular cortex; ICA = Independent Component Analyses; LARS = Lille Apathy Rating Scale; LEDD = Levodopa Equivalent Daily Dosages; MDRS = Mattis dementia rating scale; MDS-UPDRS = Movement Disorder Society Unified Parkinson Disease Rating Scale; mPFC = medial prefrontal cortex; PAS = Parkinson Anxiety Scale; PFC = prefrontal cortex; ROI = region of interest; rs-fMRI = resting state functional MRI; SDMT = Symbol digit modalities test; TMT

1 = Trail Making Test; vIPFC = ventrolateral prefrontal cortex; WAIS-R = Wechsler Adult  
2 Intelligence Scale - Revised.  
3  
4

### 5 **Disclosure of competing interests and financial support**

6  
7 No author had conflict of interests related to this study.  
8

9  
10 G. Carey was employed by Lille University Medical Center and received the EURON  
11 mobility grant which was not related to this study.  
12

13  
14 R. Lopes, R. Viard, G. Kuchcinski and Q. Devignes were employed by Lille University  
15 Medical Center and had no other financial disclosure.  
16  
17

18  
19 N. Betrouni was employed by INSERM (institut national de la santé et de la recherche  
20 médicale), received a grant from PROCOPE Campus France and gave consultancies to LLL  
21 France.  
22  
23  
24

25  
26 L. Defebvre was employed by French Government (enseignement supérieur), gave  
27 consultancies to “Abbvie” and “Orkyn” and earned honoraria for lectures from “UCB” and  
28 “Abbvie”.  
29  
30  
31

32  
33 A.F.G. Leentjens was employed by Maastricht University Medical Centre, received a grant  
34 from “Michael J Fox Foundation” and earned royalties from “Springer media” and “de  
35 Tijdstroom”.  
36  
37  
38

39  
40 K. Dujardin was employed by French Government (enseignement supérieur) and had no other  
41 financial disclosure.  
42  
43  
44

### 45 46 47 48 **Funding**

49  
50 This study used data from a study sponsored by the Michael J. Fox Foundation for  
51 Parkinson's Research. The sponsor was not involved in the design of this analysis, nor in data  
52 interpretation, the writing of this paper or decision to submit this article for publication.  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Authors credits

- 1) Research project: A. Conception, B. Organization, C. Execution;
- 2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique;
- 3) Manuscript: A. Writing of the first draft, B. Review and Critique

Guillaume Carey (1A/B/C, 2A/B, 3A); Renaud Lopes (1B/C, 2B/C, 3B); Romain Viard (1C, 2B/C, 3B); Nacim Betrouni (1C, 2B/C, 3B); Gregory Kuchcinski (2B/C, 3B); Quentin Devignes (2B/C, 3B); Luc Defebvre (1A, 2C, 3B); Albert FG Leentjens (1A, 2C, 3B); Kathy Dujardin (1A/B, 2A/C, 3B)

## Trial registration

Clinical Trials Identifier: NCT01792843

## Data availability

Data supporting the findings of this study are available from the corresponding author, upon reasonable request.

## Ethics

Written informed consent was obtained from all participants after full information of the procedure. The study was approved by the institutional ethics committees (CPP Nord-Ouest IV, 2012-A 01317-36). Additional information on this study group is detailed in the original paper.

## Word counts

Abstract = 240/ 250

Main text = 3144/3000

Items = 4/4

References = 30/30

**Abstract:**

Background: Anxiety is frequent in Parkinson’s disease (PD) and has a negative impact on disease symptoms and quality of life. The underlying mechanisms remain largely unknown. The aim of this study was to identify anatomical and functional changes associated to PD-related anxiety by comparing the volume, shape and texture of the amygdala, the cortical thickness as well as the functional connectivity (FC) the fear circuit in patients with and without clinically relevant anxiety.

Methods: Non-demented PD patients were recruited, and anxiety was quantified using the Parkinson Anxiety Scale. Structural MRI was used to compare cortical thickness and amygdala structure and resting-state functional MRI to compare FC patterns of the amygdala and resting-state functional networks in both groups.

Results: We included 118 patients: 34 with (A+) and 84 without (A-) clinically relevant anxiety. Clusters of cortical thinning were identified in the bilateral fronto-cingulate and left parietal cortices of the A+ group. The texture and the shape of the left amygdala was different in the A+ group but the overall volume did not differ between groups. FC between the amygdala and the whole brain regions did not differ between groups. The internetwork resting-state FC was higher between the “fear circuit” and salience network in the A+ group.

Conclusion: Anxiety in PD induces structural modifications of the left amygdala, atrophy of the bilateral fronto-cingulate and the left parietal cortices, and a higher internetwork resting-state FC between the fear circuit and the salience network.

## Introduction

1  
2 Anxiety is among the most frequent non-motor symptoms in Parkinson's disease (PD) with an  
3  
4 average point prevalence of 31% [1]. However, the underlying mechanisms remain poorly  
5  
6 understood. In PD patients, studies have shown a negative correlation between the level of  
7  
8 anxiety and the volume of the left amygdala, the anterior cingulate cortex (ACC) and  
9  
10 precuneus thickness [2,3]. Resting-state functional MRI (rs-fMRI) studies have shown that  
11  
12 the severity of anxiety was correlated with increased functional connectivity (FC) between the  
13  
14 amygdala and the prefrontal cortex (PFC), as well as the temporal and parietal cortices, and  
15  
16 the striatum [4,5]. These studies mostly correlated imaging data with anxiety levels, which  
17  
18 probably reflects trait anxiety (i.e. the individual's tendency to experience anxiety) [6], but  
19  
20 they did not compare patients with and without anxiety at the time of assessment, in order to  
21  
22 reveal the mechanisms of state anxiety. Nevertheless, these studies suggest dysfunction of the  
23  
24 fear circuit.  
25  
26  
27  
28  
29  
30

31 Based on animal studies, the existence of an anatomo-functional network called the "fear  
32  
33 circuit" was postulated [7] whose hub is the amygdala [8]. In humans, the amygdala is known  
34  
35 to be an interface between external stimuli and behavioral as well as cognitive responses to  
36  
37 anxiety. Functional connections between the amygdala and the anterior cingulate cortex  
38  
39 (ACC), the medial prefrontal cortex (mPFC), the insular cortex (IC), the hippocampus and the  
40  
41 striatum have been reported, that together form the human "fear circuit" [9].  
42  
43  
44

45 The aim of this study was to identify anatomical and functional changes associated with PD-  
46  
47 related anxiety by comparing the volume, shape and texture of the amygdala, the cortical  
48  
49 thickness, the FC of amygdala and the internetwork resting state FC of the fear circuit in PD  
50  
51 patients with and without clinically relevant anxiety. We assumed that changes in the fear  
52  
53 circuit will be observed in patients with anxiety, more specifically we hypothesized a smaller  
54  
55 volume of the amygdala, a smaller cortical thickness of the prefrontal, cingulate and insular  
56  
57 cortices and a higher FC within the fear circuit, compared to patients without anxiety.  
58  
59  
60  
61  
62  
63  
64  
65

## Materials and methods

### Population

This study included 156 consecutive PD patients enrolled from two movement disorders clinics in Lille (France) and Maastricht (The Netherlands) between March 2013 and August 2014. PD was diagnosed according to the United Kingdom Parkinson's Disease Society Brain Bank diagnostic criteria. Patients with other neurological disorders, as well as patients with moderate to severe dementia according to the Movement Disorders Society criteria for Parkinson's disease dementia were excluded [10].

Age, sex, duration of formal education, disease duration, history of PD or psychiatric disorders were recorded. The Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) was used to assess motor (part III), non-motor symptoms (part I) and disease severity (Hoehn-Yahr stage). The levodopa equivalent daily dosages (LEDD) were calculated and the use of antidepressant and anxiolytics treatments reported. Anxiety, depression and apathy were respectively assessed by the Parkinson Anxiety Scale (PAS) [11], the Hamilton Depression Rating Scale (HAMD) and the Lille Apathy Rating Scale (LARS). Each patient had undergone a thorough evaluation of cognitive functions (see Dujardin *et al.* [12] for details of the procedure). This evaluation assessed the overall cognitive efficiency ( Mattis dementia rating scale (MDRS)); attention and working memory (symbol digit modalities test (SDMT), forward-backward digit span subtest of the Wechsler for adults intelligence scale revised (WAIS-R)); executive functions (Trail Making Test (TMT), phonemic and alternating fluency tests); episodic memory (Hopkins verbal learning test (HVLT)); language (Boston naming test (BNT) and animal fluency) and visuospatial functions (Benton judgment of line orientation test (BJLO)).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Written informed consent was obtained from all participants after full information of the procedure. The study was approved by the institutional ethics committees (CPP Nord-Ouest IV, 2012-A 01317-36). Additional information on this study group is detailed in the original paper [12].

### **Characterization of anxiety**

Patients were divided into two groups, one with (A+) and one without (A-) anxiety, according to their score on the PAS, a scale specifically developed to detect anxiety in PD patients. We used the observer-rated version. Patients were considered “A+” if they had a score above the cut-off in at least one of the three subparts of the scale (part A (persistent anxiety) >9, part B (episodic anxiety) >3, or part C (avoidance behavior) >3) [11].

### **Imaging data acquisition**

Patients were scanned at two sites using identical 3T Philips Achieva MRI scanner (Philips Healthcare, Best, The Netherlands) with identical software versions and MR sequences. High-resolution 3D T<sub>1</sub>-weighted (3D-T<sub>1w</sub>) images were acquired with a magnetization-prepared gradient echo sequence (voxel size: 1 x 1 x 1 mm<sup>3</sup>; TR: 7.2 ms; TE: 3.3 ms; matrix size: 172 x 256 x 256 voxels; flip angle: 9°). rs-fMRI was performed with a 10 min T<sub>2</sub>\*-weighted EPI sequence (voxel size: 3 x 3 x 3 mm<sup>3</sup>; TR: 2400 ms; TE: 30 ms; matrix size: 64 x 64 x 40 voxels; flip angle: 90°). Resting-state fMRI using posterior to anterior direction with interleaved acquisition was used. Patients were required to remain quiet, stay awake and close their eyes.

### **Structural MRI analysis**

#### **Cortical thickness extraction**

To study potential cortical atrophy, cortical thickness was automatically calculated using FreeSurfer 5.3 software (<https://surfer.nmr.mgh.harvard.edu/>) from fMRIPrep tool [13].



1 Statistical analysis was implemented in Surf-Stat toolbox  
2 (<http://www.math.mcgill.ca/keith/surfstat/>) for MATLAB. The pipeline is detailed on  
3  
4 [Supplementary material, 1.a.](#)  
5  
6  
7  
8

### 9 **Volume, shape and texture of amygdala**

10  
11 Amygdala were manually segmented on 3D-T<sub>1</sub>w images with MRICRON software to bring  
12 out any atrophy. Anatomical borders were defined by a radiologist and according to literature  
13 data [14]. Volumes were recorded in mm<sup>3</sup> and normalized to the patient's total intracranial  
14 volume estimated by FreeSurfer 5.3 software. The detailed procedure is provided in  
15  
16 [Supplementary material, 1.b.](#)  
17  
18  
19  
20  
21  
22  
23

24 To study potential deformations of the amygdala, shape analysis was performed using the  
25 spherical harmonic-point discrimination model (SPHARM-PDM) [15].  
26  
27

28 A texture analysis was performed on the 3D-T<sub>1</sub>w images in order to determine changes in the  
29 amygdala. Texture analysis is an image processing method for the quantification of grey  
30 levels inside an image [16]. The procedure is detailed in Betrouni *et al* [17]. Here, we  
31 compared four first-order and seven second-order texture parameters detailed in  
32  
33 [Supplementary Table 1.](#)  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 43 **Functional MRI analysis**

#### 44 **Preprocessing and quality control**

45  
46 Common preprocessing steps, including co-registration, normalization, unwarping, noise  
47 component extraction, segmentation, skull stripping, slice-timing correction, were performed  
48 using *fMRIprep* 1.2.5 (<https://fmripred.readthedocs.io>). At the end of this procedure, an  
49 individual quality control was performed. CONN Toolbox [18] was then used for: i) Gaussian  
50 kernel 6mm smoothing; ii) to remove motion, physiological and other artefactual effects from  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 BOLD signal; iii) Band-pass filter of 0.008 Hz – 0.09 Hz (more details in [Supplementary](#)  
2 [material 1.d](#)).

### 3 4 **Resting-state functional connectivity of the amygdala**

5  
6 Resting-state FC analysis were performed with CONN. A complete brain parcellation  
7 including 91 cortical areas and 15 subcortical areas from the FSL Harvard-Oxford Atlas [19]  
8 was used to define both amygdala and the regions of interest (ROI) in MNI-space. The right  
9 and left amygdala were defined as seeds and compared to all the other ROIs. The correlation  
10 indices between the mean BOLD signal of both amygdala and of the ROIs were calculated for  
11 each patient. These correlation indices were then compared in each group and between  
12 groups.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

### 23 24 **Independent component analysis and functional network connectivity**

25  
26 Group Independent Component Analyses (ICA) were performed to identify common  
27 functional networks in patients using Calhoun’s group-level ICA approach with CONN. Forty  
28 independent components have been identified. A functional networks atlas from the *Human*  
29 *Connectome Project*, provided by the CONN Toolbox, was used to correlate common healthy  
30 functional networks with these forty components. The following networks were identified:  
31 default-mode network, left and right frontoparietal network (cognitive control), visual  
32 network, sensorimotor network and dorsal attentional network. Moreover, the salience  
33 network provided by default from the CONN toolbox was used because the group ICA failed  
34 to identify it. Finally, the “fear circuit” was defined using bilateral cortical and subcortical  
35 areas from the FSL Harvard-Oxford Atlas including amygdala, striatum, hippocampus, ACC,  
36 mPFC and IC [9]. Network masks were extracted. The correlation between the mean BOLD  
37 signal of these masks were calculated for each patient and compared in each group and  
38 between groups.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## **Statistical analyses**

For all analyses, the statistical significance threshold was set at  $p\text{-value} < 0.05$ . Correction for multiple comparisons (FDR – False Discovery rate) were performed separately for cognitive variables, functional and structural data. The normality of distribution was assessed using a Kolmogorov-Smirnov test.

### **Analysis of clinical data**

The numerical variables were described as means and standard deviations, the ordinal variables as median and range and the categorical variables as frequencies and percentages. Qualitative data were compared using Odds Ratio's and quantitative data using two sample T-tests or Mann-Whitney tests depending on normality of the distribution. These analyses were performed with the Statistical Package for the Social Sciences, version 22 (SPSS, Chicago).

### **MRI analyses**

Generalized linear models (GLM) were performed to compare cortical thickness, amygdala volumes and amygdala texture parameters between groups. Amygdala shape comparison was performed using a MANCOVA procedure. For rs-fMRI analyses, generalized linear models with permutation inference were calculated to identify significant functional connections for each group and to compare these connections between the groups.

### **Regression analysis**

Hierarchical multiple regression post-hoc analyses were performed to examine the relationship between the PAS score and sub-scores and the volume and texture of amygdala, mean cortical thickness in the significant clusters and FC values. Center, sex and Hoehn-Yahr stage were set as nuisance regressors in the first block (model 1) of all regression models whereas PAS score or sub-scores (independent variable) were separately added to the second block (model 2) of the model to examine the association between anxiety symptoms and imaging data, adjusted by the effect of center, sex and Hoehn-Yahr stage. We ensured that all

1 models met the assumptions of multiple regression analyses, including normality of the  
2 residuals, multicollinearity and homoscedasticity.  
3  
4  
5  
6

## 7 **Results**

### 8 **Population**

9  
10 After exclusion of 38 patients for dementia (n=14), refusal or contraindication to have an MRI  
11 (n=22) or unusable MRI (major motion artefact – n = 2), 118 were involved in the present  
12 study, 34 with (“A+”) and 84 without (“A-”) anxiety ([Flowchart in Supplementary Figure 1](#)).  
13  
14  
15  
16  
17  
18  
19  
20  
21

### 22 **Demographic and clinical variables**

23  
24 “A+” patients were more frequently female, with a family history of PD, and more often a  
25 left-sided onset of motor symptoms. MDS-UPDRS part I sub-scores of depression, anxiety,  
26 sleep disturbances, pain, and fatigue were higher in “A+” group than in the “A-” group and  
27 disease stage was more advanced. In the “A+” group, LEDD was higher and antidepressants  
28 and anxiolytics were used more frequently ([Table 1](#)).  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

### 39 **Cognitive variables**

40  
41 After FDR-correction for multiple comparisons, patients in the “A+” group had lower results  
42 at backward digit span and animal fluency test as well as a slower processing speed than in  
43 the “A-” group ([Table 1](#)).  
44  
45  
46  
47  
48  
49  
50

### 51 **Structural analyses**

52 All following analyses were adjusted for sex, disease stage and center.  
53  
54  
55

#### 56 **Cortical thickness**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Three clusters of reduced cortical thickness were identified in the bilateral frontal and left parietal regions in the “A+” compared to “A-” group (Figure 1). There was no significant difference for the reverse analysis.

### **Volume, shape and texture of amygdala**

There was no significant group difference for the volume of amygdala (A+/A-, left: 1201 mm<sup>3</sup> / 1284mm<sup>3</sup>; right: 1210 mm<sup>3</sup> / 1273 mm<sup>3</sup>). Shape analysis revealed several remodeling areas located on the medial and postero-lateral sides of the left amygdala. Texture analyses showed a significant group difference for the second-order texture value “correlation”, in the left amygdala (F=3.86, p=0.025) (Figure 2).

### **Functional analyses**

#### **Functional connectivity of the amygdala**

Of the 118 patients, 17 were excluded from the FC analyses after quality control (n=101). Their demographic and clinical characteristics (presented in Supplementary Table 2) were similar as the original study population.

There were fewer functional connections with both amygdala in the “A+” than in “A-” group. However, after FDR-correction, there was no longer any significant difference (Supplementary Figure 2 and Supplementary Table 3).

#### **Resting-state functional networks and the fear circuit**

In the “A+” group, the FC was significantly higher between the fear circuit and the salience network (F-score = 2.55, FDR-corrected p-value = 0.0375), compared to “A-” group.

#### **Regression analyses**

The PAS score was significantly positively related to the FC between the left amygdala-left parahippocampal cortex (p=0.010). The PAS-B sub-score was significantly negatively related to the mean cortical thickness of the left fronto-cingulate (p=0.003), right fronto-cingulate

1 (p=0.013) and left parietal areas (p=0.016). The PAS-C sub-score was significantly negatively  
2 related to the mean cortical thickness of the left fronto-cingulate cluster (p=0.016) and  
3  
4 positively related to the FC between the left amygdala-left parahippocampal cortex (p=0.011).  
5  
6  
7 There were no other significant associations. (Figure 3 and Supplementary Table 4).  
8  
9

## 11 **Discussion**

12 The present study sought to identify anatomical and functional markers of PD-related anxiety.  
13  
14 We observed reduced cortical thickness of the bilateral fronto-cingulate and left parietal  
15  
16 regions, and anatomical changes of the left amygdala in PD patients with anxiety, with several  
17  
18 remodeling areas located on the medial and postero-lateral sides of the left amygdala and  
19  
20 changes in texture). Moreover, FC between the fear circuit and the salience network was  
21  
22 higher in the "A+" group.  
23  
24  
25  
26  
27  
28  
29  
30

### 31 **PD-related anxiety is associated with changes in the left amygdala**

32 A negative correlation between the severity of anxiety in PD and the volume of the left  
33  
34 amygdala was previously reported [2]. However, we did not find any between group  
35  
36 difference in the volume of the amygdala, this volume was not associated with the severity of  
37  
38 anxiety symptoms as measured by the PAS. However, shape analyses revealed a remodeling  
39  
40 area at the medial and postero-lateral sides of the left amygdala in the "A+" group. Moreover,  
41  
42 this structural remodeling of the left amygdala altered the image texture. The lower  
43  
44 "correlation" texture parameter in anxious patients may be interpreted as a reduction of the  
45  
46 MRI signal consistency. Overall, these results support the role of the amygdala in PD-related  
47  
48 anxiety. However, the rather subtle anatomical modifications suggest that the amygdala is not  
49  
50 the only structure involved in PD-related anxiety, but more part of a complex system  
51  
52 including the "fear circuit" as well as other structures.  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2 **Anxiety in PD is associated with cortical atrophy in the fear circuit**  
3

4 We observed clusters of cortical thinning in the bilateral fronto-cingulate and left parietal  
5 cortices. Moreover, the mean cortical thickness of these clusters was negatively associated  
6  
7 with the severity of anxiety, especially for episodic anxiety (PAS-B) and avoidance behavior  
8  
9 (PAS-C).  
10  
11

12  
13 As these areas are parts of the fear circuit, their thinning could contribute to disruption of fear  
14 processing and thus promote anxiety. In the A+ group, the mPFC, ventrolateral PFC (vlPFC)  
15 and dorsolateral PFC (dlPFC) had less cortical thickness. In the fear circuit, the vlPFC would  
16  
17 be involved in salience detection and action inhibition whereas the dlPFC would be involved  
18  
19 in allocation of attentional resources to salient information and cognitive regulation [20–22].  
20  
21

22  
23 Authors suggested an impaired voluntary emotion regulation by the lateral PFC along with an  
24 increased automatic emotion regulation by the mPFC in PD patients with anxiety [4]. These  
25  
26 regions are also involved in more general cognitive processes and related to cognitive  
27  
28 deficits in PD [23]. Furthermore, smaller cortical thickness of the cingulate cortex could  
29  
30 contribute to intrusive negative thoughts that may underlie anxiety symptoms [3]. It could  
31  
32 lead to attentional resources disturbance, as found in this study. The parietal cortex has also  
33  
34 been involved in PD-related anxiety (precuneus, supramarginalis cortex) [3]. It would be  
35  
36 involved in internal awareness and adaptation after environment changes, which possibly  
37  
38 explains the difficulty of anxious individuals diverting attention from their negative thoughts  
39  
40 [5,24].  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

51  
52  
53 **PD-related anxiety is associated with changes in the FC between networks**  
54

55 The FC between the “fear circuit” and the salience network was significantly increased in the  
56  
57 “A+” group. The salience network is involved in stimuli identification in order to adapt  
58  
59  
60  
61  
62  
63  
64  
65

1 behavior. It is an interface between cognition, emotion and somatic manifestations. It is  
2 therefore involved in “bottom-up” attentional processing and could lead to hypervigilance in  
3  
4 case of insufficient filtering of these stimuli [25]. These results suggest that any event (e.g.  
5  
6 changes in habits, unexpected situations, ...) would be disproportionately perceived in “A+”  
7  
8 patients. It would then promote anxious manifestations by letting intrusive thoughts and  
9  
10 negative emotions to occur. It could worsen anxiety in a vicious circle.  
11  
12

13  
14 We also observed a trend toward a significant between-group difference of the FC of the  
15  
16 amygdala, as well as a positive association between the severity of anxiety and the FC of the  
17  
18 left amygdala with the left parahippocampal gyrus, especially for avoidance behavior (PAS-  
19  
20 C). Similar associations have been previously reported [5]. Hence, anxiety in PD is associated  
21  
22 with a higher activation of the brain fear circuit, led by a higher temporo-amygdala  
23  
24 connectivity, which could interfere with other structures.  
25  
26  
27  
28  
29  
30

### 31 **Anxiety is associated with clinical and cognitive features in PD**

32  
33  
34 Female gender, left-sided motor symptoms onset, severity of the disease, the presence of other  
35  
36 non-motor symptoms and higher drug use have already been associated with PD-related  
37  
38 anxiety [26,27]. Only few studies examined cognitive features of PD patients with anxiety. In  
39  
40 this study, “A+” patients had lower scores in attention, working memory and language. This  
41  
42 is in line with a previous study showing that, in PD, state anxiety predicts performance in  
43  
44 these cognitive domains [28]. Anxiety could thus worsen PD-associated cognitive  
45  
46 dysfunctions. We hypothesize that by focusing their attention on anxiety-inducing topics,  
47  
48 anxious patients would divert attentional resources, leading to less efficient cognitive control.  
49  
50  
51 In return, these cognitive difficulties may increase anxiety. However, the place of cognitive  
52  
53 impairment as cause or consequence of anxiety symptoms in PD remains very controversial  
54  
55  
56  
57  
58 [29,30].  
59  
60  
61  
62  
63  
64  
65



## 1 2 **Limitations**

3  
4 Firstly, the “A+” patients were considered to have significant anxiety symptoms according to  
5  
6 their score at the PAS but did not have a formal diagnosis of any specific anxiety disorder  
7  
8 according to diagnostic criteria. However, the PAS has demonstrated high sensitivity and  
9  
10 specificity as a diagnostic test for anxiety disorders in PD [11]. Secondly, anxiety is a  
11  
12 continuous symptom. Interpreting it using a cut-off value could be a potential limitation since  
13  
14 a certain proportion of subjects obtained a score close to this threshold (the distribution is  
15  
16 shown in [Supplementary Figure 3](#)). Thirdly, despite between-group differences, statistical  
17  
18 analyses were not adjusted on medication status and depression. As both groups had similar  
19  
20 severity of motor symptoms, it is highly probable that the difference in LEDD was related to  
21  
22 anxiety. Introducing it as a covariate would have reduce the effect of anxiety. Regarding  
23  
24 depression, only few patients had clinically relevant depressive symptoms and we considered  
25  
26 that such correction would have distort reality. Finally, the lack of a healthy control group did  
27  
28 not enable us to determine which findings are specific to PD and which are for anxiety in  
29  
30 general.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

## 41 **Conclusion**

42  
43 Structural and functional changes in the human brain fear circuit, including the amygdala, the  
44  
45 fronto-cingulate and parietal cortex, play a role in anxiety in PD. These changes could also  
46  
47 explain associated cognitive features, such as lower attention. However, alterations within the  
48  
49 fear circuit are probably not the only mechanism. Further studies are needed to better explain  
50  
51 its link with the physiopathology of the disease.  
52  
53  
54  
55  
56  
57

## 58 **Acknowledgment**

1 The authors thank all participants of the study for their patience and cooperation, Marie  
2 Delliaux, Anja Moonen for their help in neuropsychological assessment, Eugenie Mutez for  
3  
4 her help in clinical assessment and the In-vivo Imaging and Functions core facility (CI2C –  
5  
6 <http://www.ci2c.fr>) the MRI acquisitions and image processing.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## References

- 1  
2 [1] M.P.G. Broen, N.E. Narayan, M.L. Kuijf, N.N.W. Dissanayaka, A.F.G. Leentjens,  
3 Prevalence of anxiety in Parkinson's disease: A systematic review and meta - analysis,  
4 Movement Disord. 31 (2016) 1125–1133. doi:10.1002/mds.26643.  
5  
6 [2] C. Vriend, P.S. Boedhoe, S. Rutten, H.W. Berendse, Y.D. van der Werf, O.A. van den  
7 Heuvel, A smaller amygdala is associated with anxiety in Parkinson's disease: a combined  
8 FreeSurfer—VBM study, J Neurology Neurosurg Psychiatry. 87 (2016) 493–500.  
9 doi:10.1136/jnnp-2015-310383.  
10  
11 [3] N. Wee, M.-C. Wen, N. Kandiah, R.J. Chander, A. Ng, W.L. Au, L.C.S. Tan, Neural  
12 correlates of anxiety symptoms in mild Parkinson's disease: A prospective longitudinal voxel-  
13 based morphometry study, J Neurol Sci. 371 (2016) 131–136. doi:10.1016/j.jns.2016.10.021.  
14  
15 [4] R. Dan, F. Růžička, O. Bezdicek, E. Růžička, J. Roth, J. Vymazal, G. Goelman, R. Jech,  
16 Separate neural representations of depression, anxiety and apathy in Parkinson's disease, Sci  
17 Rep-Uk. 7 (2017) 12164. doi:10.1038/s41598-017-12457-6.  
18  
19 [5] H. Zhang, Y. Qiu, Y. Luo, P. Xu, Z. Li, W. Zhu, Q. Wu, W. Tao, Q. Guan, F. Chen, The  
20 relationship of anxious and depressive symptoms in Parkinson's disease with voxel-based  
21 neuroanatomical and functional connectivity measures, J Affect Disorders. 245 (2019) 580–  
22 588. doi:10.1016/j.jad.2018.10.364.  
23  
24 [6] P.C. Leal, T.C. Goes, L.C.F. da Silva, F. Teixeira-Silva, Trait vs. state anxiety in different  
25 threatening situations, Trends Psychiatry Psychotherapy. 39 (2017) 147–157.  
26 doi:10.1590/2237-6089-2016-0044.  
27  
28 [7] P. Tovote, J.P. Fadok, A. Lüthi, Neuronal circuits for fear and anxiety, Nat Rev Neurosci.  
29 16 (2015) 317–331. doi:10.1038/nrn3945.  
30  
31 [8] A.K. Roy, Z. Shehzad, D.S. Margulies, A.M.C. Kelly, L.Q. Uddin, K. Gotimer, B.B.  
32 Biswal, F.X. Castellanos, M.P. Milham, Functional connectivity of the human amygdala  
33 using resting state fMRI, Neuroimage. 45 (2009) 614–626.  
34 doi:10.1016/j.neuroimage.2008.11.030.  
35  
36 [9] L.M. Shin, I. Liberzon, The Neurocircuitry of Fear, Stress, and Anxiety Disorders, Focus.  
37 9 (2011) 311–334. doi:10.1176/foc.9.3.foc311.  
38  
39 [10] M. Emre, D. Aarsland, R. Brown, D.J. Burn, C. Duyckaerts, Y. Mizuno, G.A. Broe, J.  
40 Cummings, D.W. Dickson, S. Gauthier, J. Goldman, C. Goetz, A. Korczyn, A. Lees, R. Levy,  
41 I. Litvan, I. McKeith, W. Olanow, W. Poewe, N. Quinn, C. Sampaio, E. Tolosa, B. Dubois,  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2 Clinical diagnostic criteria for dementia associated with Parkinson's disease, *Movement Disord.* 22 (2007) 1689–1707. doi:10.1002/mds.21507.

3 [11] A.F.G. Leentjens, K. Dujardin, G.M. Pontone, S.E. Starkstein, D. Weintraub, P.  
4 Martinez-Martin, The Parkinson Anxiety Scale (PAS): Development and validation of a new  
5 anxiety scale, *Movement Disord.* 29 (2014) 1035–1043. doi:10.1002/mds.25919.

6 [12] K. Dujardin, A.J.H. Moonen, H. Behal, L. Defebvre, A. Duhamel, A.A. Duits, L.  
7 Plomhause, C. Tard, A.F.G. Leentjens, Cognitive disorders in Parkinson's disease:  
8 Confirmation of a spectrum of severity, *Parkinsonism Relat D.* 21 (2015) 1299–1305.  
9 doi:10.1016/j.parkreldis.2015.08.032.

10 [13] O. Esteban, C.J. Markiewicz, R.W. Blair, C.A. Moodie, A.I. Isik, A. Erramuzpe, J.D.  
11 Kent, M. Goncalves, E. DuPre, M. Snyder, H. Oya, S.S. Ghosh, J. Wright, J. Durnez, R.A.  
12 Poldrack, K.J. Gorgolewski, fMRIPrep: a robust preprocessing pipeline for functional MRI,  
13 *Nat Methods.* 16 (2019) 111–116. doi:10.1038/s41592-018-0235-4.

14 [14] A. Siozopoulos, V. Thomaidis, P. Prassopoulos, A. Fiska, In vivo estimation of normal  
15 amygdala volume from structural MRI scans with anatomical-based segmentation, *Surg*  
16 *Radiol Anat.* 40 (2018) 145–157. doi:10.1007/s00276-017-1915-y.

17 [15] M. Styner, I. Oguz, S. Xu, C. Brechbühler, D. Pantazis, J.J. Levitt, M.E. Shenton, G.  
18 Gerig, Framework for the Statistical Shape Analysis of Brain Structures using SPHARM-  
19 PDM., *Insight J.* (2006) 242–250.

20 [16] R.M. Haralick, K. Shanmugam, I. Dinstein, Textural Features for Image Classification,  
21 *Ieee Transactions Syst Man Cybern.* SMC-3 (1973) 610–621.  
22 doi:10.1109/tsmc.1973.4309314.

23 [17] N. Betrouni, R. Lopes, L. Defebvre, A.F.G. Leentjens, K. Dujardin, Texture features of  
24 magnetic resonance images: A marker of slight cognitive deficits in Parkinson's disease.,  
25 *Mov Disord Official J Mov Disord Soc.* 35 (2020) 486–494. doi:10.1002/mds.27931.

26 [18] S. Whitfield-Gabrieli, A. Nieto-Castanon, Conn: A Functional Connectivity Toolbox for  
27 Correlated and Anticorrelated Brain Networks, *Brain Connectivity.* 2 (2012) 125–141.  
28 doi:10.1089/brain.2012.0073.

29 [19] R.S. Desikan, F. Ségonne, B. Fischl, B.T. Quinn, B.C. Dickerson, D. Blacker, R.L.  
30 Buckner, A.M. Dale, R.P. Maguire, B.T. Hyman, M.S. Albert, R.J. Killiany, An automated  
31 labeling system for subdividing the human cerebral cortex on MRI scans into gyral based  
32 regions of interest, *Neuroimage.* 31 (2006) 968–980. doi:10.1016/j.neuroimage.2006.01.021.

33 [20] D.T. Stuss, M.P. Alexander, Executive functions and the frontal lobes: a conceptual  
34 view, *Psychological Res.* 63 (2000) 289–298. doi:10.1007/s004269900007.

- 1  
2 [21] D.T. Stuss, Frontal lobes and attention: Processes and networks, fractionation and  
3 integration, *J Int Neuropsych Soc.* 12 (2006) 261–271. doi:10.1017/s1355617706060358.  
4  
5 [22] D.T. Stuss, Functions of the Frontal Lobes: Relation to Executive Functions, *J Int*  
6 *Neuropsych Soc.* 17 (2011) 759–765. doi:10.1017/s1355617711000695.  
7  
8 [23] C.S. Oosterwijk, C. Vriend, H.W. Berendse, Y.D. van der Werf, O.A. van den Heuvel,  
9 Anxiety in Parkinson’s disease is associated with reduced structural covariance of the  
10 striatum, *J Affect Disorders.* 240 (2018) 113–120. doi:10.1016/j.jad.2018.07.053.  
11  
12 [24] G. Hartwigsen, H.R. Siebner, Joint Contribution of Left Dorsal Premotor Cortex and  
13 Supramarginal Gyrus to Rapid Action Reprogramming, *Brain Stimul.* 8 (2015) 945–952.  
14 doi:10.1016/j.brs.2015.04.011.  
15  
16 [25] V. Menon, Brain Mapping: Saliency Network, *Syst.* 2 (2015) 597–611.  
17 doi:10.1016/b978-0-12-397025-1.00052-x.  
18  
19 [26] A.F.G. Leentjens, K. Dujardin, L. Marsh, P. Martinez-Martin, I.H. Richard, S.E.  
20 Starkstein, Symptomatology and markers of anxiety disorders in Parkinson’s disease: A cross-  
21 sectional study, *Movement Disord.* 26 (2011) 484–492. doi:10.1002/mds.23528.  
22  
23 [27] N.N.N.W. Dissanayaka, E. White, J.D. O’Sullivan, R. Marsh, N.A. Pachana, G.J. Byrne,  
24 The clinical spectrum of anxiety in Parkinson’s disease, *Movement Disord.* 29 (2014) 967–  
25 975. doi:10.1002/mds.25937.  
26  
27 [28] K.A.E. Martens, C.R.A. Silveira, B.N. Intzandt, Q.J. Almeida, State anxiety predicts  
28 cognitive performance in patients with Parkinson’s disease., *Neuropsychology.* 32 (2018)  
29 950–957. doi:10.1037/neu0000478.  
30  
31 [29] N.N.W. Dissanayaka, R.A. Lawson, A.J. Yarnall, G.W. Duncan, D.P. Breen, T.K. Khoo,  
32 R.A. Barker, D.J. Burn, I.-P. study group, Anxiety is associated with cognitive impairment in  
33 newly-diagnosed Parkinson’s disease, *Parkinsonism Relat D.* 36 (2017) 63–68.  
34 doi:10.1016/j.parkreldis.2017.01.001.  
35  
36 [30] A.J. Petkus, J.V. Filoteo, D.M. Schiehser, M.E. Gomez, G. Petzinger, Worse cognitive  
37 performance predicts increased anxiety and depressive symptoms in patients with Parkinson’s  
38 disease: A bidirectional analysis., *Neuropsychology.* 33 (2018) 35–46.  
39 doi:10.1037/neu0000498.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Tables



<b>Demographic variables</b>	A+ group (n = 34)	A- group (n = 84)	OR (CI 95%); p-value	
Age (years)	65.62 (± 7.66)	64.10 (± 8.62)	0.37	
Women (n = 36)	16 (47.06%)	20 (23.81%)	<b>2.84 (1.23; 6.58); p = 0.013*</b>	
Hand dominance (right, n = 101)	29 (85.29%)	72 (85.71%)	0.97 (0.31; 3); p = 0.99	
Formal education (years)	12.12 (± 3.96)	12.61 (± 3.53)	0.51	
Illness duration (years)	9.59 (± 7.82)	8.18 (± 4.99)	0.25	
First motor side <i>Left (n = 48)</i>	20 (58.82%)	28 (33.33%)	<b>3.21 (1.31; 7.85); p = 0.009*</b>	
<b>Clinical variables</b>				
LEDD (mg/day)	937.36 (± 494.38)	732.53 (± 578.12)	<b>0.02*</b>	
Antidepressant use (n = 17)	13 (38.24%)	4 (4.76%)	<b>12.38 (3.66; 41.91); p &lt; 0.0001*</b>	
Anxiolytic use (n = 12)	10 (29.41%)	2 (2.38%)	<b>17.08 (3.5; 83.33); p &lt; 0.0001*</b>	
MDS-UPDRS part 1 (0 - 4) §				
1.3. Depressed mood	1 (0 - 4)	0 (0 - 4)	<b>0.001*</b>	
1.4. Anxious mood	2 (0 - 4)	0 (0 - 4)	<b>&lt; 0.0001*</b>	
1.7. Night-time sleep problems	2 (0 - 4)	2 (0 - 4)	<b>0.03*</b>	
1.8. Daytime sleepiness	2 (0 - 4)	2 (0 - 4)	0.26	
1.9. Pain and other sensations	2 (0 - 4)	1 (0 - 4)	<b>&lt; 0.0001*</b>	
1.10. Urinary problems	1 (0 - 4)	1 (0 - 4)	0.09	
1.11. Constipation problems	1 (0 - 4)	0 (0 - 4)	0.10	
1.12. Lightheadedness on standing	1 (0 - 3)	0 (0 - 3)	0.28	
1.13. Fatigue	2 (0 - 4)	1 (0 - 4)	<b>0.03*</b>	
MDS-UPDRS part 3 (/132)	30.2 (± 14.9)	28.1 (± 12.0)	0.54	
Hoehn & Yahr stage (0 - 5) §	2 (1 - 5)	2 (0 - 4)	<b>0.003*</b>	
PAS total (/48)	14.79 (± 4.69)	3.69 (± 2.87)	<b>&lt; 0.0001*</b>	
Part A (/20)	9.47 (± 4.32)	2.85 (± 2.87)	<b>&lt; 0.0001*</b>	
Part B (/16)	2.38 (± 2.26)	0.42 (± 0.85)	<b>&lt; 0.0001*</b>	
Part C (/12)	2.94 (± 2.32)	0.43 (± 0.85)	<b>&lt; 0.0001*</b>	
HAMD total (/54)	8.7 (± 5.2)	4.5 (± 3.6)	<b>&lt; 0.0001*</b>	
HARS total (/56)	11.4 (± 5.8)	5.3 (± 4.2)	<b>&lt; 0.0001*</b>	
<b>Cognitive variables</b>	A+ group (n = 34)	A- group (n = 84)	Uncorrected p-value	FDR-corrected p-value
<u>Overall efficiency</u>				
MDRS score (/144)	136 (± 5.90)	138 (± 6.62)	0.024	0.096
<u>Attention and working memory</u>				
WAIS-R forward digit (/14)	7.12 (± 2.14)	7.90 (± 2.19)	0.06	0.120
WAIS-R backward digit (/14)	4.88 (± 1.87)	6.04 (± 1.67)	0.001	<b>0.008*</b>
SDMT: number in 90 s	35.35 (± 10.57)	44.71 (± 11.91)	0.00009	<b>0.001*</b>
<u>Executive functions</u>				
TMT (time B/time A)	2.75 (± 0.91)	2.47 (± 0.71)	0.09	0.131
Stroop: interference index	2.04 (± 0.70)	1.75 (± 0.47)	0.024	0.077
Phonemic fluency: words in 60 s	11.97 (± 4.19)	13.75 (± 4.84)	0.06	0.107
Alternating fluency: words in 60 s	10.74 (± 3.89)	12.04 (± 4.85)	0.12	0.137
<u>Episodic memory</u>				
HVLTLearn 1 (/12)	5.79 (± 1.81)	6.64 (± 1.92)	0.03	0.080
HVLTLearn total (/36)	24.31 (± 4.30)	26.27 (± 4.43)	0.04	0.091
HVLTLearned recall (/12)	8.62 (± 1.92)	9.04 (± 2.69)	0.09	0.120
HVLTLearned recognition hits (/12)	11.32 (± 0.88)	11.24 (± 1.26)	0.78	0.780
HVLTLearned number of intrusions	1.75 (± 2.05)	1.50 (± 2.13)	0.37	0.395
<u>Language</u>				
Boston Naming Test (/15)	12.26 (± 2.31)	13.00 (± 1.96)	0.09	0.111
Semantic fluency: animals in 60s	16.94 (± 4.60)	20.71 (± 5.91)	0.001	<b>0.005*</b>
<u>Visuospatial functions</u>				
Benton Judgment of Line Orientation	10.71 (± 3.26)	11.95 (± 2.55)	0.08	0.128

1 **Table 1. Demographic, clinical and cognitive variables: group comparisons (Parkinson’s**  
2 **disease patients with (A+) and without (A-) anxiety).**

3  
4 \* = FDR-corrected *p*-value < 0.05, § = described as median and range ; CI = confidence  
5 interval; HAMD = Hamilton Depression Rating Scale; HARS = Hamilton Anxiety Rating  
6 Scale; HVLT = Hopkins verbal learning test; LARS = Lille Apathy Rating Scale; LEDD =  
7 Levodopa Equivalent Daily Dosages; MDRS = Mattis dementia rating scale; MDS-UPDRS =  
8 Movement Disorder Society Unified Parkinson Disease Rating Scale; OR = Odds Ratio; PAS  
9 = Parkinson Anxiety Scale; SDMT = Symbol digit modalities test; TMT = Trail Making Test;  
10 WAIS-R = Wechsler for adults intelligence scale revised.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



## Figures




	Cluster	Size (mm <sup>2</sup> )	T-max	Talairach coordinates			Location
				X	Y	Z	
Right hemisphere	1	2060.59	6.320	10.5	19.9	55.1	<b>Superior frontal gyrus</b> Inferior frontal gyrus (oper) Inferior frontal gyrus (tri) Middle frontal gyrus
Left hemisphere	1	4986.41	6.901	-7.4	23.3	41.5	<b>Superior frontal gyrus</b> Cingulate (anterior) gyrus Cingulate (posterior) gyrus
	2	1703.03	5.406	-60.6	-27.8	29.7	<b>Supra-marginalis gyrus</b>

### Figure 1. Cortical thickness analysis.

(a) Map of reduced cortical thickness clusters in patients with anxiety compared to patients without anxiety (T-score). (b) Boxplots of cortical thickness comparisons for the four significant clusters of cortical thickness reduction in the Parkinson's disease patients with (A+) and without (A-) anxiety, adjusted by sex. (c) Location and MRI coordinates of cortical thickness atrophy clusters in Parkinson's disease patients with anxiety compared to patients without anxiety.

\* = FDR-corrected  $p$ -value < 0.05; **Bold** = T-max gyrus; oper = opercularis; tri. = triangularis.




**Figure 2. Anatomical changes of left amygdala in A+ compared to A- patients in PD, adjusted by center, sex and Hoehn-Yarh stage.**

*Shape analysis:* (a) statistical map, (b) signed distance map (mm) and (c) vertex map showing significant shape differences on the medial and inferior sides of the left amygdala.

*Texture analysis:* (d) distribution of the second-order texture parameter "correlation" in left amygdala between the two groups.



Ant. = Anterior side; Inf. = Inferior side; Lat. = Lateral side; Med. = Medial side; Sup. = Superior side.



**Figure 2. Regression of the PAS score and sub-scores with the mean cortical thickness of the right fronto-cingulate (a), the left fronto-cingulate (b, d), the left parietal cluster (c) and with the functional connectivity values between the left amygdala and left parahippocampal cortex (e, f).**

*Abbreviation: HY = Hoehn & Yahr stage; PaHC = parahippocampal cortex; PAS = Parkinson Anxiety Scale.*

Figure 1  
[Click here to download high resolution image](#)



	Cluster	Size (mm <sup>2</sup> )	T-max	Talairach coordinates			Location
				X	Y	Z	
Right hemisphere	1	2060.59	6.320	10.5	19.9	55.1	Superior frontal gyrus Inferior frontal gyrus (oper) Inferior frontal gyrus (tri) Middle frontal gyrus
Left hemisphere	1	4986.41	6.901	-7.4	23.3	41.5	Superior frontal gyrus Cingulate (anterior) gyrus Cingulate (posterior) gyrus
	2	1703.03	5.406	-60.6	-27.8	29.7	Supra-marginalis gyrus

**c.**

Figure 2

[Click here to download high resolution image](#)




Figure 3

[Click here to download high resolution image](#)

